Uracil mustard was used for the treatment of thrombocytosis in 14 patients, eight who had polycythemia vera and six who had essential thrombocytosis. Intermittent treatment with 1 to 2 mg/day for 14 days was used for most patients, and continuous treatment was used for three patients. The nadir of the platelet count occurred during a mean period of five to seven weeks, and the mean duration between courses was seven months. The drug selectively depressed the platelet count, with a minimal effect on leukocytes and erythrocytes. Uracil mustard is an effective drug for the control of thrombocytosis.
(JAMA 244:1454-1455, 1980)
Shamasunder HK, Gregory SA, Knospe WH. Uracil Mustard in the Treatment of Thrombocytosis. JAMA. 1980;244(13):1454–1455. doi:10.1001/jama.1980.03310130032024
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: